United Therapeutics [UTHR] vs Zoetis [ZTS] Detailed Stock Comparison

United Therapeutics

NASDAQ
Loading...

Zoetis

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: United Therapeutics wins in 14 metrics, Zoetis wins in 5 metrics, with 0 ties. United Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricUnited TherapeuticsZoetisBetter
P/E Ratio (TTM)16.9224.68United Therapeutics
Price-to-Book Ratio2.6812.77United Therapeutics
Debt-to-Equity Ratio0.00137.01United Therapeutics
PEG Ratio1.771.41Zoetis
EV/EBITDA10.1117.38United Therapeutics
Profit Margin (TTM)40.36%27.83%United Therapeutics
Operating Margin (TTM)45.64%40.20%United Therapeutics
EBITDA Margin (TTM)45.64%40.20%United Therapeutics
Return on Equity19.30%52.77%Zoetis
Return on Assets (TTM)12.96%15.37%Zoetis
Free Cash Flow (TTM)$1.08B$2.30BZoetis
Dividend YieldN/A1.11%N/A
1-Year Return24.59%-26.34%United Therapeutics
Price-to-Sales Ratio (TTM)6.376.76United Therapeutics
Enterprise Value$16.14B$68.57BZoetis
EV/Revenue Ratio5.247.31United Therapeutics
Gross Profit Margin (TTM)89.03%73.62%United Therapeutics
Revenue per Share (TTM)$69$21United Therapeutics
Earnings per Share (Diluted)$25.12$5.80United Therapeutics
Beta (Stock Volatility)0.620.89United Therapeutics
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

United Therapeutics vs Zoetis Stock Performance Analysis

Loading Price Chart...

United Therapeutics
Zoetis
United Therapeutics Stock Overview | Zoetis Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
United Therapeutics1.20%4.24%9.54%50.21%42.01%23.10%
Zoetis1.51%-1.63%-7.29%-7.89%-11.87%-11.75%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
United Therapeutics24.59%114.46%326.34%258.80%694.13%1,312.23%
Zoetis-26.34%-3.23%-12.26%233.57%362.75%362.75%

News Based Sentiment: United Therapeutics vs Zoetis

United Therapeutics

News based Sentiment: MIXED

September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.

View United Therapeutics News Sentiment Analysis

Zoetis

News based Sentiment: MIXED

The month featured both positive developments – the CVMP opinion for Portela® and generally positive analyst estimates – alongside negative signals like stock decline, technical warnings, and mixed institutional activity. This creates a balanced, rather than decisively positive or negative, investment narrative.

View Zoetis News Sentiment Analysis

Performance & Financial Health Analysis: United Therapeutics vs Zoetis

MetricUTHRZTS
Market Information
Market Cap i$19.33B$63.73B
Market Cap CategoryLarge capN/A
10 Day Avg. Volume i924,0012,724,607
90 Day Avg. Volume i904,0242,517,512
Last Close$443.44$167.10
52 Week Range$266.98 - $444.57$139.70 - $200.33
% from 52W High-0.25%-16.59%
All-Time High$444.57 (Oct 02, 2025)$249.27 (Dec 27, 2021)
% from All-Time High-0.25%-32.96%
Growth Metrics
Quarterly Revenue Growth0.12%0.04%
Quarterly Earnings Growth0.11%0.15%
Financial Health
Profit Margin (TTM) i0.40%0.28%
Operating Margin (TTM) i0.46%0.40%
Return on Equity (TTM) i0.19%0.53%
Debt to Equity (MRQ) i0.00137.01
Cash & Liquidity
Book Value per Share (MRQ)$158.65$11.21
Cash per Share (MRQ)$67.41$3.28
Operating Cash Flow (TTM) i$1.37B$2.93B
Levered Free Cash Flow (TTM) i$811.05M$2.29B
Dividends
Last 12-Month Dividend Yield iN/A1.11%
Last 12-Month Dividend iN/A$1.86

Valuation & Enterprise Metrics Analysis: United Therapeutics vs Zoetis

MetricUTHRZTS
Price Ratios
P/E Ratio (TTM) i16.9224.68
Forward P/E i15.2522.57
PEG Ratio i1.771.41
Price to Sales (TTM) i6.376.76
Price to Book (MRQ) i2.6812.77
Market Capitalization
Market Capitalization i$19.33B$63.73B
Enterprise Value i$16.14B$68.57B
Enterprise Value Metrics
Enterprise to Revenue i5.247.31
Enterprise to EBITDA i10.1117.38
Risk & Other Metrics
Beta i0.620.89
Book Value per Share (MRQ) i$158.65$11.21

Financial Statements Comparison: United Therapeutics vs Zoetis

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)UTHRZTS
Revenue/Sales i$794.40M$2.22B
Cost of Goods Sold i$92.50M$622.00M
Gross Profit i$701.90M$1.60B
Research & Development i$149.00M$157.00M
Operating Income (EBIT) i$382.80M$846.00M
EBITDA i$449.40M$991.00M
Pre-Tax Income i$423.50M$810.00M
Income Tax i$101.30M$179.00M
Net Income (Profit) i$322.20M$631.00M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)UTHRZTS
Cash & Equivalents i$1.90B$1.72B
Total Current Assets i$3.94B$5.88B
Total Current Liabilities i$721.50M$3.39B
Long-Term Debt iN/A$5.40B
Total Shareholders Equity i$6.81B$4.66B
Retained Earnings i$7.54B$12.38B
Property, Plant & Equipment i$0$6.36B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)UTHRZTS
Operating Cash Flow i$463.80M$567.00M
Capital Expenditures i$-74.90MN/A
Free Cash Flow i$386.30M$438.00M
Debt Repayment i$-100.00MN/A
Common Stock Repurchase i$0$-443.00M

Short Interest & Institutional Ownership Analysis

MetricUTHRZTS
Shares Short i2.78M7.76M
Short Ratio i3.122.40
Short % of Float i0.08%0.02%
Average Daily Volume (10 Day) i924,0012,724,607
Average Daily Volume (90 Day) i904,0242,517,512
Shares Outstanding i44.83M448.47M
Float Shares i42.01M442.31M
% Held by Insiders i0.02%0.00%
% Held by Institutions i1.00%0.99%

Dividend Analysis & Yield Comparison: United Therapeutics vs Zoetis

MetricUTHRZTS
Last 12-Month Dividend iN/A$1.86
Last 12-Month Dividend Yield iN/A1.11%
3-Year Avg Annual Dividend iN/A$1.63
3-Year Avg Dividend Yield iN/A0.24%
3-Year Total Dividends iN/A$4.90
Ex-Dividend DateN/AApr 21, 2025